[artículo]
| Título : |
A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder |
| Tipo de documento: |
texto impreso |
| Autores: |
Douglas E. Feltner, Autor ; Jerri G. Crockatt, Autor ; Steven J. Dubovsky, Autor |
| Fecha de publicación: |
2023 |
| Artículo en la página: |
pp. 240-249 |
| Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
| Palabras clave: |
Trastornos de ansiedad, Pruebas Neuropsicológicas, Pregabalina, Ácido gamma-aminobutírico. |
| Resumen: |
Pregabalin is a novel compound under development for the treatment of several types of anxiety disorders. To obtain an initial evaluation of the efficacy and safety of pregabalin in the treatment of generalized anxiety disorder (GAD), we conducted a double-blind, fixed-dose, parallel-group, placebo and active-controlled multicenter 4-week study that compared 271 patients randomized to receive pregabalin 50 mg tid (N = 70), pregabalin 200 mg tid (N = 66), placebo (N = 67), or lorazepam 2 mg tid (N = 68), followed by a 1-week double-blind taper. |
| Link: |
./index.php?lvl=notice_display&id=31020 |
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 240-249
[artículo] A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder [texto impreso] / Douglas E. Feltner, Autor ; Jerri G. Crockatt, Autor ; Steven J. Dubovsky, Autor . - 2023 . - pp. 240-249. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 240-249
| Palabras clave: |
Trastornos de ansiedad, Pruebas Neuropsicológicas, Pregabalina, Ácido gamma-aminobutírico. |
| Resumen: |
Pregabalin is a novel compound under development for the treatment of several types of anxiety disorders. To obtain an initial evaluation of the efficacy and safety of pregabalin in the treatment of generalized anxiety disorder (GAD), we conducted a double-blind, fixed-dose, parallel-group, placebo and active-controlled multicenter 4-week study that compared 271 patients randomized to receive pregabalin 50 mg tid (N = 70), pregabalin 200 mg tid (N = 66), placebo (N = 67), or lorazepam 2 mg tid (N = 68), followed by a 1-week double-blind taper. |
| Link: |
./index.php?lvl=notice_display&id=31020 |
|
A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 3 (Junio)
